Latest news
December 4, 2025
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment
January 12, 2023
Debiopharm Applies Extended-Release Formulation Expertise To Reduce Treatment Frequency Burden For Acromegaly & GEP-NET Patients